Jennifer Michaelson Sells 4,000 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock

Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 4,000 shares of the business's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $12.51, for a total value of $50,040.00. Following the completion of the sale, the insider now owns 95,760 shares of the company's stock, valued at approximately $1,197,957.60. This represents a 4.01 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Jennifer Michaelson also recently made the following trade(s):

• On Wednesday, December 18th, Jennifer Michaelson sold 4,693 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $11.41, for a total transaction of $53,547.13.
• On Thursday, December 12th, Jennifer Michaelson sold 3,489 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $12.52, for a total transaction of $43,682.28.
• On Tuesday, November 5th, Jennifer Michaelson sold 8,000 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $15.64, for a total transaction of $125,120.00.

Cullinan Therapeutics Stock Performance

NASDAQ:CGEM traded down $0.22 during trading hours on Tuesday, hitting $11.56. The company's stock had a trading volume of 385,276 shares, compared to its average volume of 372,219. The company has a market capitalization of $673.12 million, a PE ratio of -4.07 and a beta of -0.14. Cullinan Therapeutics, Inc. has a 52-week low of $10.00 and a 52-week high of $30.19. The business's 50-day moving average is $13.38 and its two-hundred day moving average is $15.97.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.09. As a group, analysts predict that Cullinan Therapeutics, Inc. will post -3.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Cullinan Therapeutics

Several institutional investors have recently modified their holdings of the company. Deerfield Management Company L.P. Series C raised its holdings in Cullinan Therapeutics by 188.1% during the second quarter. Deerfield Management Company L.P. Series C now owns 3,280,237 shares of the company's stock worth $57,207,000 after purchasing an additional 2,141,706 shares during the last quarter. State Street Corp grew its stake in Cullinan Therapeutics by 20.4% in the 3rd quarter. State Street Corp now owns 2,337,222 shares of the company's stock valued at $39,125,000 after acquiring an additional 396,034 shares during the last quarter. RTW Investments LP increased its holdings in Cullinan Therapeutics by 62.1% during the 3rd quarter. RTW Investments LP now owns 1,705,960 shares of the company's stock valued at $28,558,000 after acquiring an additional 653,330 shares in the last quarter. Holocene Advisors LP lifted its holdings in shares of Cullinan Therapeutics by 16.5% in the third quarter. Holocene Advisors LP now owns 1,533,579 shares of the company's stock valued at $25,672,000 after purchasing an additional 217,574 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Cullinan Therapeutics by 23.8% in the third quarter. Geode Capital Management LLC now owns 1,208,421 shares of the company's stock valued at $20,233,000 after purchasing an additional 231,935 shares during the last quarter. Hedge funds and other institutional investors own 86.31% of the company's stock.

Analyst Upgrades and Downgrades

CGEM has been the subject of several analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $28.00 price objective on shares of Cullinan Therapeutics in a research note on Wednesday, October 16th. Wedbush reaffirmed an "outperform" rating and set a $36.00 price target on shares of Cullinan Therapeutics in a report on Wednesday, September 18th. Finally, UBS Group assumed coverage on shares of Cullinan Therapeutics in a research note on Thursday, October 24th. They issued a "buy" rating and a $30.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $31.67.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.